Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
ConditionAdvanced Prostate Cancer
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexMale
Age19+
SponsorDongkook Pharmaceutical Co., Ltd.
About this trial
A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.
Eligibility criteria
Qualifiers
Adult male aged 19 or older
Histologically or cytologically-confirmed prostate cancer
Serum testosterone level >150 ng/dL
ECOG PS grade ≤ 2
Disqualifiers
History of surgical procedures such as testicular resection, adrenal resection, and pituitary resection
History of hormone therapy
History of 5α-reductase inhibitor
History of radical radiation therapy
Trial design
Treatments tested in this trial
- DKF-MA102
Treatment groups
154 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov